uniQureQURE
Recorded

uniQure 2026 Q2 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ2 2026Duration54 minParticipants19

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, thank you for standing by. My name is Joy, I will be your conference operator today. At this time, I would like to welcome everyone to the uniQure Second Quarter 2026 Earnings Call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question-and-answer session. If you would like to ask a question during this time, simply press star followed by the number 1 on your telephone keypad. If you would like to withdraw your question, press star 1 again. We kindly ask that you please limit your questions to one and one follow-up. Thank you. I would now like to turn the call over to Chiara Russo, Senior Director of Investor Relations.

Chiara RussoSenior Director of Investor Relations

Please go ahead, ma'am. Good morning, thank you for joining us for uniQure's second quarter of 2026 earnings call.

Chiara RussoSenior Director of Investor Relations

Earlier this morning, uniQure released financial results second quarter of 2026, our press release is available on the Investors and Media section of our website at uniqure.com. Our 10-Q was also filed with the SEC earlier today. Joining me on the call this morning are Matt Kapusta, Chief Executive Officer, Dr. Walid Abi-Saab, Chief Medical Officer, Kylie O'Keefe, Chief Customer and Strategy Officer, Christian Klemt, our Chief Financial Officer. After our formal remarks, we'll open up the call for Q&A. Before we begin, please know that we will be making forward-looking statements during this investor call. All statements other than statements of historical fact are forward-looking statements. They are based on management's beliefs and assumptions and on information available to management only as of the date of this conference call.

Chiara RussoSenior Director of Investor Relations

Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the factors described in uniQure's most recent SEC filings. Given these risks, you should not place undue reliance on these forward-looking statements, we assume no obligation to update these statements, even if new information becomes available in the future. Now, let me introduce Matt Kapusta, uniQure's CEO.

Matt KapustaCEO

Thanks, Chiara. Good morning, thank you for joining us this morning. The second quarter was an important one for uniQure. We received guidance from both the FDA and MHRA on near-term regulatory pathways for AMT-130, announced promising early data from our Fabry disease and refractory temporal lobe epilepsy programs, strengthened our balance sheet into 2030 through a follow-on offering. Taken together, these developments meaningfully advance our ability to deliver transformative therapies to patients with serious unmet needs. On today's call, I will provide a brief overview of the quarter before turning to Walid for an update on our clinical programs, Kylie on commercial readiness, Christian on the financials. I will offer some closing remarks before opening the call to analyst questions. I want to start with AMT-130 and the progress we have made with our FDA interactions.

Matt KapustaCEO

In June 2026, we held a Type B meeting with the FDA, during which we reached alignment with the FDA that a BLA submission under the Accelerated Approval pathway for AMT-130 based on the three-year data is reasonable. This alignment was later confirmed in the final meeting minutes we recently received. FDA asked to align the confirmatory study design prior to the BLA submission, including the consideration of a randomized standard of control design instead of a sham procedure. Additionally, consistent with the agency's January 2025 draft published guidance for Accelerated Approvals, the FDA stated that the confirmatory study should be feasible to conduct within a reasonable timeframe and be well underway and potentially fully enrolled at the time of Accelerated Approval. We are fully committed to initiating the confirmatory trial as soon as possible after alignment has been reached.

Matt KapustaCEO

The FDA recognizes that HD is a serious disease with a high unmet need for safe and effective therapies. We are working collaboratively with them on a confirmatory study design. We are on track to submit the BLA this quarter. Walid will provide additional details later in the call. In parallel, after a successful pre-submission meeting with the Medicines and Healthcare products Regulatory Agency, or MHRA, earlier this year, our U.K. regulatory submission is also on track as planned for the third quarter. Also in the third quarter, we expect to conduct our four-year AMT-130 data analyses from the Phase I/II studies. We look forward to presenting the four-year data results in September. Beyond AMT-130, we are encouraged by the progress across our broader pipeline.

Matt KapustaCEO

Early data from our Phase I/II-A study of AMT-260 in refractory mesial temporal lobe epilepsy and Phase I/II study of AMT-191 in Fabry disease continue to support the potential of both programs. We look forward to sharing further updates in the first half of next year. As we prepare for potential commercialization of AMT-130, our team has intensified its focus and execution. We are deeply engaged with the Huntington's Disease Centers of Excellence, payers, and the patient community. We are working diligently to put in place the infrastructure to support what we hope will be a timely and successful product launch. In summary, we are entering the second half of the year with strong momentum, clear regulatory pathways for AMT-130 in the U.S. and U.K., advancing pipeline programs, and a customer-focused commercial organization prepared to deliver.

Matt KapustaCEO

We are grateful to the FDA for their continued engagement and collaboration, to the MHRA for their constructive interactions. Above all, to the patients, families, investigators, and advocates in the Huntington's disease community whose resilience and trust continue to inspire us every day. With that, I will turn the call over to Walid to provide additional detail on AMT-130 and our broader pipeline.

Walid Abi-SaabChief Medical Officer

Walid? Thank you, Matt. Good morning and good afternoon, everyone.

Walid Abi-SaabChief Medical Officer

I'll start with AMT-130 and Huntington's disease. As Matt noted, the Type B meeting with the FDA was a pivotal moment for this program and the HD community. At this meeting, the FDA communicated that our three-year phase I/II data would be acceptable as the primary basis of a BLA for the Accelerated Approval of AMT-130. The FDA also requested that we align on the design of the confirmatory trial to support Accelerated Approval prior to BLA submission. We're working with the FDA to finalize the design of the confirmatory study. The critical point is that the FDA agreed that a randomized study using sham control is no longer required. The agency recommended instead that we run a randomized standard-of-care controlled study with Total Functional Capacity at 36 months as the primary endpoint.

Walid Abi-SaabChief Medical Officer

We are committed to conducting the global confirmatory study and will work diligently to ensure that the study is completed with a reasonable timeline. We remain on track for a third quarter BLA submission and look forward to potentially bringing this therapy to patients. On the ex-U.S. regulatory strategy, as Matt noted earlier, we are on track with our planned regulatory activities with the MHRA. With our near-term regulatory focus on the U.S. and the U.K., we expect to engage more fully with the European Medicines Agency in 2027 and remain committed to bringing AMT-130 to patients across Europe in due course. Turning to our clinical progress, I'm very pleased to report that the AMT-130 clinical team is on track with data quality and database lock activities based on the June 30th cutoff date for the four-year data, keeping us on schedule for the expected September update.

Walid Abi-SaabChief Medical Officer

We currently plan to disclose safety and tolerability data through four years of follow-up. The update will also include top-line data from 12 high and 12 low-dose patients at four years, with an additional three patients at the high dose for a total of 15 patients now with three years of follow-up. Clinical data will include cUHDRS and its components, such as TFC, compared to a propensity-score-matched natural history control derived from the Enroll-HD database. We continue to believe Enroll-HD provides a robust and contemporaneous comparator, and we are pleased that CHDI has afforded us the opportunity to incorporate the latest iteration of the Enroll-HD database into the four-year analysis, which has been recently updated with approximately 6,000 additional HD participants for a total of approximately 26,000 participants to draw from. We also plan on providing CSF NfL change from baseline at four years.

Walid Abi-SaabChief Medical Officer

Moving on to AMT-260 for refractory mesial temporal lobe epilepsy. This quarter brought the first cohort-level readout from the phase I/II study, which we presented at a medical conference in June. As of May 29th, 2026, data cut off, three of six patients in the first low-dose cohort achieved meaningful reductions in disabling seizures during months four through six, ranging from 79%-100% below baseline. The remaining three patients showed variable outcomes over the same period, ranging from a 33% decrease to a 36% increase from baseline. On safety, as of the presentation date, there were no serious adverse events related to AMT-260 or the surgical procedure.

Walid Abi-SaabChief Medical Officer

All adverse events in the low dose cohort were mild or moderate, most commonly headache in two patients, and no immunosuppression was required. We view this tolerability profile, combined with early signals of biological activity as supportive of continued evaluation at the higher dose. Enrollment in the second higher dose cohort is expected to complete imminently. Updated results for both cohorts are expected in the first half of 2027. Lastly, I will cover AMT-191 for Fabry disease. In June of this year, we presented updated preliminary safety and exploratory efficacy data from the phase I/II study with a March 15, 2026, cutoff date. Patient follow-up ranged from three months to more than 18 months. Consistent with our disclosure in February, dose-dependent elevations of alpha Gal A activity were observed in all 11 patients across 3 dose levels.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day